Abstract Tablets may be defined as solid pharmaceutical dosage forms containing drug substances with or without suitable diluents and prepared either by compression or molding methods. They have been in widespread use since the latter part of the 19th century and their popularity continues. In the present study inlay tablets of an anti-inflammatory drug was formulated and evaluated. The tablet is most widely used dosage form because of its ease of administration, compactness and ease of manufacturing. The aim of study is to formulate combination of an anti-inflammatory agent and proteolytic enzyme for oral delivery system, which helps in wound healing process. Drugs are used to treat osteoarthritis; rheumatoid arthritis, it is also used to treat acute and chronic pain and inflammation. The primary object of the present study is to formulate a robust, stable version of tablet containing an anti-inflammatory agent (Sulindac) and proteolytic enzyme (Serratiopeptidase) for the treatment on osteoarthritis and rheumatoid arthritis. Sulindac is newly invented NSAID which reduces pain and inflammation while Serratiopeptidase reduce swelling and pus formation. The combination of both agents help in wound healing process. The drug was analysed and drug sample was found to comply with all specification. In this work, tablets were prepared by using Inlay approach to provide satisfactory drug release. The prepared tablets were also evaluated for physical appearance, thickness, diameter, hardness, weight variation, friability, disintegration time and in vitro drug release.
Keywords Anti-inflammatory, Inlay, Serratiopeptidase, Sulindac.